174 related articles for article (PubMed ID: 37179357)
21. Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo.
Yalcin TE; Ilbasmis-Tamer S; Takka S
Int J Pharm; 2020 Apr; 580():119246. PubMed ID: 32205141
[TBL] [Abstract][Full Text] [Related]
22. Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer.
Smith T; Affram K; Nottingham EL; Han B; Amissah F; Krishnan S; Trevino J; Agyare E
Sci Rep; 2020 Oct; 10(1):16989. PubMed ID: 33046724
[TBL] [Abstract][Full Text] [Related]
23. Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models.
Kawaguchi K; Miyake K; Zhao M; Kiyuna T; Igarashi K; Miyake M; Higuchi T; Oshiro H; Bouvet M; Unno M; Hoffman RM
Cell Cycle; 2018; 17(16):2019-2026. PubMed ID: 29963961
[TBL] [Abstract][Full Text] [Related]
24. A Nanoparticle Carrier for Co-Delivery of Gemcitabine and Small Interfering RNA in Pancreatic Cancer Therapy.
Li J; Chen Y; Zeng L; Lian G; Chen S; Li Y; Yang K; Huang K
J Biomed Nanotechnol; 2016 Aug; 12(8):1654-66. PubMed ID: 29342344
[TBL] [Abstract][Full Text] [Related]
25. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer.
Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake M; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Wangsiricharoen S; Bouvet M; Singh SR; Unno M; Hoffman RM
Cancer Lett; 2018 Sep; 432():251-259. PubMed ID: 29928962
[TBL] [Abstract][Full Text] [Related]
26. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
27. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
28. Novel Gemcitabine Conjugated Albumin Nanoparticles: a Potential Strategy to Enhance Drug Efficacy in Pancreatic Cancer Treatment.
Kushwah V; Agrawal AK; Dora CP; Mallinson D; Lamprou DA; Gupta RC; Jain S
Pharm Res; 2017 Nov; 34(11):2295-2311. PubMed ID: 28795274
[TBL] [Abstract][Full Text] [Related]
29. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
[TBL] [Abstract][Full Text] [Related]
30. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
Zhao X; Li F; Li Y; Wang H; Ren H; Chen J; Nie G; Hao J
Biomaterials; 2015 Apr; 46():13-25. PubMed ID: 25678112
[TBL] [Abstract][Full Text] [Related]
31. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
33. Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging.
Affram K; Udofot O; Singh M; Krishnan S; Reams R; Rosenberg J; Agyare E
PLoS One; 2017; 12(9):e0185116. PubMed ID: 28934281
[TBL] [Abstract][Full Text] [Related]
34. Lipid-like gemcitabine diester-loaded liposomes for improved chemotherapy of pancreatic cancer.
Wang X; Lu H; Luo F; Wang D; Wang A; Wang X; Feng W; Wang X; Su J; Liu M; Xia G
J Control Release; 2024 Jan; 365():112-131. PubMed ID: 37981050
[TBL] [Abstract][Full Text] [Related]
35. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model.
Kawaguchi K; Igarashi K; Miyake K; Lwin TM; Miyake M; Kiyuna T; Hwang HK; Murakami T; Delong JC; Singh SR; Clary B; Bouvet M; Unno M; Hoffman RM
Tissue Cell; 2018 Jun; 52():124-128. PubMed ID: 29857821
[TBL] [Abstract][Full Text] [Related]
36. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
[TBL] [Abstract][Full Text] [Related]
37.
Yang H; Tong Z; Shen L; Sun YU; Hoffman RM; Huang J
Anticancer Res; 2020 Sep; 40(9):4969-4978. PubMed ID: 32878785
[TBL] [Abstract][Full Text] [Related]
38. Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma.
Roife D; Dai B; Kang Y; Perez MVR; Pratt M; Li X; Fleming JB
Clin Cancer Res; 2016 Dec; 22(24):6021-6030. PubMed ID: 27259561
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
40. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model.
Guo P; Ma J; Li S; Guo Z; Adams AL; Gallo JM
Cancer Chemother Pharmacol; 2001 Aug; 48(2):169-76. PubMed ID: 11561783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]